The Seraseq® Antepartum and Postpartum SMA Male – Matched cfDNA reference materials are designed to support the development, validation, and performance monitoring of Next-Generation Sequencing (NGS) and other amplified nucleic acid-based methods used in Spinal Muscular Atrophy (SMA) screening via Non-Invasive Prenatal Testing (NIPT).
Seraseq® Antepartum SMA Male cfDNA (Cat# 0720-1115)
Sourced from the blood of a pregnant patient carrying a male fetus with confirmed SMA
Designed to mimic real-world SMA-High-Risk NIPT samples
Seraseq® Postpartum SMA Male cfDNA (Cat# 0720-1129)
Derived from the same patient’s blood collected after birth
Ideal for fetal fraction limit of detection studies, assay calibration, and dilution-based sensitivity testing
Supplied as purified cfDNA in 0.1X TE buffer, the Antepartum SMA Male cfDNA (cat# 0720-1115), can be used as a reference material in assay development, validation, verification, analysis and routine monitoring of test performance as well as troubleshooting and training. It can be either used as supplied or diluted using the matching Seraseq Postpartum SMA Male cfDNA (cat# 0720-1129), in order to custom fetal fraction levels and perform limit of detection (LoD) studies.
FEATURES AND BENEFITS
Clinically sourced: derived from naturally occurring cfDNA from a gestation diagnosed with SMA.
The only reference material compatible with a broad range of NIPT methods, including SNP-based NIPT assays.
Proprietary method preserves native cfDNA characteristics such as size profile of ~170 bp, SNP content and natural maternal-fetal size difference. This ensures the material behaves like patient samples.
High-quality Quality Assured 3rd party control: lot-to-lot consistency with materials manufactured in GMP-compliant and ISO 13485-certified facilities under strict quality controls.
Easy to use & highly stable: supplied as purified cfDNA in 0.1X TE buffer with 4 years long shelf-life and which can be added during the library preparation step
